News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Gentium S.p.A. Reports Second Quarter Financial Results; Provides Phase II/III Pediatric Prevention Trial and Financial Update
December 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
VILLA GUARDIA, Italy--(BUSINESS WIRE)--Gentium S.p.A. (NASDAQ: GENT) (the “Company”) today provided an update regarding the Phase II/III pediatric prevention trial and reported financial results for the quarter ended June 30, 2008.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
Earnings
Europe
MORE ON THIS TOPIC
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
·
4 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH TACONIC BIOSCIENCES
The ‘Research Safety Net’ Saving Scientists from Funding Crisis
September 4, 2025
·
1 min read
·
Lori Ellis
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
September 4, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study
September 3, 2025
·
2 min read
·
Tristan Manalac
